Close Menu

Curetis

For 2019, the firm's total revenues from commercial operations, licensing, and collaborations are expected to grow to more than €3 million.

Under the agreement, Menarini will immediately begin distributing Curetis' PCR-based system in Germany, France, Benelux, the UK, and Switzerland.

The companies have signed a licensing agreement related to bioinformatics tools to enable antimicrobial resistance research.

The submission by Curetis' distribution partner Beijing Clear Biotech used data previously collected for regulatory approvals in the US and Europe.

The new regulatory approvals add to previous approvals in Singapore, expanding the firm's reach in the Association of Southeast Asian Nations region.

New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.

The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.

The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.

The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.

Pages

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.